630 5TH AVENUE, NEW YORK, NY
Provides Corporate Update, Announces Completion of Clinical Conduct of ADME and DDI Clinical Studies
Receives FDA Clearance of its IND Application for Blarcamesine in Fragile X Syndrome
Material disclosure
Other Events
Regains Compliance with Nasdaq Periodic Filing Requirement
Reports Third Fiscal Quarter 2026 Financial Results and Business Update
Investor Presentation
Highlights Highly Qualified Board and Decisive Actions to Create Long-Term Value for Stockholders
Amended Annual Report
Q3
Amended Quarterly Report
Notice of Late Filing for Quarterly Report
Q1
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
S-3ASR
Definitive Additional Information Statement
Additional Proxy Materials
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Submission Upload
Correspondence
Post-Effective Amendment to Registration Statement